TB-500 (Thymosin Beta-4) is a 43-amino acid peptide with a uniquely systemic healing profile — stem cell mobilization, systemic anti-inflammation, and cardiovascular protection. For women, its whole-body mechanism makes it particularly effective for overtraining syndrome, multi-site injuries, and chronic inflammatory conditions.
TB-500 binds G-actin and upregulates the LKKTET sequence of Thymosin β4, mobilizing stem cells and progenitor cells to injury sites. This systemic mechanism makes TB-500 uniquely effective for multi-site injuries or widespread inflammation — a common pattern in women with overtraining syndrome or autoimmune-driven inflammation.
Reduces systemic inflammation via NF-κB pathway modulation and anti-inflammatory cytokine regulation. Unlike NSAIDs, TB-500 reduces inflammation without impairing the healing cascade — it suppresses destructive inflammation while preserving the anabolic signaling required for tissue repair.
TB-500 promotes endothelial cell migration and new blood vessel formation, supporting cardiovascular health and tissue perfusion. Research in cardiac models shows TB-500 reduces post-injury fibrosis and supports myocardial repair — relevant for women with cardiovascular risk factors or exercise-induced cardiac stress.
TB-500 is dosed weekly rather than daily — its systemic mechanism and longer half-life allow for less frequent administration than BPC-157.
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Loading (Weeks 1–4) | 2–5 mg twice/week | SubQ, 2x weekly | Start at 2 mg if new to peptides. Increase to 5 mg if well-tolerated. |
| Loading (Weeks 5–6) | 2–5 mg once/week | SubQ, 1x weekly | Transition to weekly dosing as tissue levels stabilize. |
| Maintenance (Weeks 7–12) | 2–5 mg biweekly | SubQ, every 2 weeks | Maintenance phase. Continue until full recovery or as ongoing protocol. |
| Stack with BPC-157 | 2 mg TB-500 + 250 mcg BPC-157 | TB-500 weekly, BPC daily | Classic recovery stack. Inject separately at different sites. |
| Benefit | Evidence Level | Mechanism | Timeframe |
|---|---|---|---|
| Systemic anti-inflammatory | Strong (rodent + anecdote) | NF-κB modulation, cytokine regulation | 2–3 weeks |
| Tendon/ligament repair | Strong (rodent models) | Stem cell mobilization, actin signaling | 4–8 weeks |
| Muscle recovery | Moderate | Satellite cell activation, anti-inflammatory | 2–4 weeks |
| Cardiovascular protection | Moderate (cardiac models) | Endothelial migration, anti-fibrotic | 6–12 weeks |
| Overtraining recovery | Moderate (anecdote) | Systemic inflammation reduction | 2–4 weeks |
≥99% purity, third-party COA verified. Use code HEALTH for 15% off.
Shop TB-500 at Purgo LabsTB-500 (Thymosin Beta-4) is researched in women for systemic anti-inflammatory effects, connective tissue repair, cardiovascular protection, and stem cell mobilization. Women commonly use it for chronic injury recovery, overtraining syndrome, and as a complement to BPC-157 for comprehensive healing protocols. Its systemic mechanism makes it particularly effective for widespread inflammation or multi-site injuries.
Research protocols for women typically use 2–5 mg per week, administered subcutaneously. A common loading protocol is 2–5 mg twice weekly for 4–6 weeks, followed by a maintenance phase of 2–5 mg once weekly or biweekly. Women may start at the lower end (2 mg/week) and titrate based on response. Cycle length is typically 6–12 weeks.
TB-500 does not directly affect estrogen, progesterone, or other sex hormones. It modulates systemic inflammation and immune function via actin-binding and stem cell mobilization mechanisms. Reduced systemic inflammation may indirectly support hormonal balance by lowering the inflammatory burden on the HPO axis, but TB-500 has no direct hormonal activity.
Yes — the TB-500 + BPC-157 stack is one of the most well-established peptide combinations. BPC-157 provides local tissue repair via FAK-paxillin signaling and VEGF upregulation, while TB-500 provides systemic anti-inflammatory effects and stem cell mobilization. The combination addresses both local and systemic aspects of injury recovery simultaneously and is widely used in women's sports medicine protocols.
TB-500 has a favorable safety profile in research with no documented estrogenic, anti-estrogenic, or androgenic effects. It does not suppress the HPTA axis. The most common side effects are mild injection site reactions and transient fatigue in the first 1–2 weeks. There is no human safety data for use during pregnancy or breastfeeding — avoid in these contexts.
Most research subjects report reduced systemic inflammation and improved recovery within 2–3 weeks of starting TB-500. Structural tissue repair (tendon, ligament, muscle) typically shows measurable improvement at 4–6 weeks. The systemic nature of TB-500 means its effects are often felt more broadly than BPC-157 — energy, recovery speed, and general inflammation reduction are common early indicators.
BPC-157 is primarily a local tissue repair agent — most effective when injected near the injury site for targeted healing. TB-500 is a systemic agent — it mobilizes stem cells and reduces inflammation throughout the body, making it better suited for widespread inflammation, multiple injury sites, or overtraining syndrome. Many women use both simultaneously for comprehensive recovery.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.